BANZEL is indicated for adjunctive treatment of seizures associated with
Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older,
and in adults.
To register or log in, CLICK HERE ►
Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial
Register now to receive updates and resources
Take part in this peer-to-peer program